Seattle Genetics Initiates Phase 1 Trial of SEA-BCMA in Relapsed or Refractory Multiple Myeloma Patients
Seattle Genetics is recruiting patients with relapsed or…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Darzalex Extends Time to Disease Progression, Death Among Newly Diagnosed Multiple Myeloma Patients, Phase 3 Trial Shows
Multiple myeloma patients who are not eligible for high-dose chemotherapy…
Excessive RNA Editing Linked to Myeloma Progression, Treatment Resistance, Study Suggests
Abnormally high production of an RNA editing enzyme called…
FDA Grants Poseida’s P-BCMA-101 RMAT Status for Treatment of Multiple Myeloma
The U.S. Food and Drug Administration (FDA)Â …
FDA Clears Way for Trials of FOR46 in Late-stage Multiple Myeloma, Prostate Cancer
The U.S. Food and Drug Administration has allowed Fortis…
FDA Approves Empliciti Combination for Relapsed or Refractory Multiple Myeloma
The U.S. Food and Drug Administration has approved…
